Cargando…

Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)

Survivin is one of the inhibitors of apoptosis proteins (IAP) that might play an important role in the pathogenesis of diffuse large B cell lymphoma (DLBCL). The present study was designed to investigate the clinical and prognostic significance of survivin expression in nodal DLBCL. We analyzed lymp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markovic, O., Marisavljevic, D., Cemerikic-Martinovic, V., Martinovic, T., Filipovic, B., Stanisavljevic, D., Živković, R., Hajder, J., Stanisavljevic, N., Mihaljevic, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505514/ https://www.ncbi.nlm.nih.gov/pubmed/22528517 http://dx.doi.org/10.1007/s12032-012-0232-x

Ejemplares similares

Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients
por: Otasevic, Vladimir, et al.
Publicado: (2022)

Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients
por: Stanisavljevic, Natasa, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (Procyon lotor)
por: D’Annunzio, Giulia, et al.
Publicado: (2022)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Renal cancer and Wegener's granulomatosis: a case report
por: Bumbasirevic, Uros, et al.
Publicado: (2011)

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
por: Castellino, A., et al.
Publicado: (2018)

Primary Extra-Nodal DLBCL of Glands: Our Experiences outside Guidelines of Treatment
por: Sica, Antonello, et al.
Publicado: (2021)

Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Markers, Disease
Publicado: (2023)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified
por: Itami, Hiroe, et al.
Publicado: (2021)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
por: Griffiths, Robert, et al.
Publicado: (2010)

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)
por: Feng, Pengcheng, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL)
por: Whooley, Peter D., et al.
Publicado: (2018)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Basic-Kinda, S., et al.
Publicado: (2022)

Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma
por: Hu, Shaoxuan, et al.
Publicado: (2022)

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
por: Lehners, Nicola, et al.
Publicado: (2017)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Kaposi's Sarcoma Presenting as Acute Small Bowel Obstruction Diagnosed on Multidetector Computed Tomography with Histopathological Correlation
por: Halankar, Jaydeep, et al.
Publicado: (2015)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients
por: Schif, Birgit, et al.
Publicado: (2012)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
por: Regier, Dean A., et al.
Publicado: (2022)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

Paraneoplastic Necrotizing Myelopathy in a Patient With Newly Diagnosed Diffuse Large B Cell Lymphoma
por: Lee, Chau Hung, et al.
Publicado: (2011)

Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
por: Yoshida, Masahiro, et al.
Publicado: (2021)

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
por: Bhalla, Kavita, et al.
Publicado: (2018)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
por: Coughlan, Monica, et al.
Publicado: (2014)

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling
por: Greenbaum, Adam M., et al.
Publicado: (2022)

Extra- and Intracranial Diffuse Large B-Cell Lymphoma (DLBCL) Mimicking Meningioma: A Case Report and Literature Review
por: Matejka, Matthias, et al.
Publicado: (2023)

Genetic diversity of newly diagnosed follicular lymphoma
por: Asmann, Y W, et al.
Publicado: (2014)

Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis
por: Zhang, Ya, et al.
Publicado: (2015)

Prognostic Significance of Microvessel Density Determining by Endoglin in Stage II Rectal Carcinoma: A Retrospective Analysis
por: Martinovic, Zeljko, et al.
Publicado: (2015)

Recurrences in stage II rectal carcinoma after curative resection alone: from the viewpoint of angiogenesis
por: Martinović, Željko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_snno0revgka1dvf7u8kpd2oe4i